Lorazepam Tablets Recalled Due to Incorrect Strength Labeling
Leading Pharma, LLC is recalling Lorazepam tablets labeled as 0.5 mg but containing 1 mg. The recall addresses a labeling error affecting 2,952 bottles nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a labeling error that could result in temporary or medically reversible health consequences. The hazard is a strength mislabeling (0.5 mg vs 1 mg) without reported injuries.
Plain-English summary
Leading Pharma, LLC is voluntarily recalling 2,952 bottles of Lorazepam Tablets, USP CIV, 0.5 mg, 500-count. The recall is due to a labeling error where bottles labeled as containing 0.5 mg tablets actually contained 1 mg tablets of lorazepam.
The affected product is identified by Lot #E00717 and NDC 69315-904-05. The product was distributed nationwide in the USA. Lorazepam is a prescription-only medication classified as a benzodiazepine.
Consumers and healthcare providers should check their inventory for bottles with Lot #E00717. If found, the product should be returned to the pharmacy or distributor for a refund or replacement. Patients should consult their healthcare provider if they have questions regarding their medication.
The recalled product
- Product
- LORAZEPAM (LORAZEPAM)
- Brand
- LORAZEPAM
- Manufacturer
- Leading Pharma, LLC
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot #E00717
UPCs (9)
- 0369315905104
- 0369315904053
- 0369315904107
- 0369315906101
- 0369315906057
- 0369315905050
- 0369315904015
- 0369315905012
- 0369315906019
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LORAZEPAM
- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled Due to Sub-Potency and Failed Stability Testing
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam injection vials recalled for elevated impurities and degradation
FDA (Drugs) · 2023-05-24
Same manufacturer · Leading Pharma, LLC
See all →- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29
- HighAntidepressant Medication Recalled for Excessive Active Ingredient Potency
FDA (Drugs) · 2022-10-05
Same hazard · mis labeling
See all →- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- HighSura Tanmen Ramen Noodles Recalled for Undeclared Fish Allergens
FDA (Food) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02